[1] Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma[J]. Am J Hematol, 1994, 47(4):278-282. DOI: 10.1002/ajh.2830470406.
[2] Awasthi NP, Qayoom S, Dabadghao S. Blastic plasmacytoid dendritic cell neoplasm presenting as leukemia without cutaneous lesion[J]. J Cancer Res Ther, 2017, 13(6): 1056-1058. DOI: 10.4103/0973-1482.220358.
[3] Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumors. WHO classification of tumours of haematopoietic and lymphoid tissues[M]. Lyon: IARC Press, 2008: 226-228.
[4] Solary E, Itzykson R. How I treat chronic myelomonocytic leukemia[J]. Blood, 2017, 130(2): 126-136. DOI: 10.1182/blood-2017-04-736421.
[5] Beird HC, Khan M, Wang F, et al. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN)[J]. Blood Cancer J, 2019, 9(12): 99. DOI: 10.1038/s41408-019-0262-0.
[6] Pagano L, Valentini CG, Grammatico S, et al. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches[J]. Br J Haematol, 2016, 174(2): 188-202. DOI: 10.1111/bjh.14146.
[7] Riaz W, Zhang L, Horna P, et al. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy[J]. Cancer Control, 2014, 21(4): 279-289. DOI: 10.1177/107327481402100404.
[8] Laribi K, Baugier de Materre A, Sobh M, et al. Blastic plasmacytoid dendritic cell neoplasms: results of an international survey on 398 adult patients[J]. Blood Adv, 2020, 4(19): 4838-4848. DOI: 10.1182/bloodadvances. 2020002474.
[9] Kolerova A, Sergeeva I, Krinitsyna J, et al. Blastic plasmacytoid dendritic cell neoplasm: case report and literature overview[J]. Indian J Dermatol, 2020, 65(3): 217-221. DOI: 10.4103/ijd.IJD_235_18.
[10] Zaki MMAF, Zalata K, El-Hawary AK, et al. Blastic plasmacytoid dendritic cell neoplasm: a case report and clinicopathological review[J]. J Hematol, 2018, 7(3): 124-127. DOI: 10.14740/jh428w.
[11] Pemmaraju N, Sweet KL, Stein AS, et al. Long-term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm[J]. J Clin Oncol, 2022, 40(26): 3032-3036. DOI: 10.1200/JCO.22.00034.
[12] Hu Z, Sun T. Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia[J]. Blood, 2016, 128(12): 1664. DOI: 10.1182/blood-2016- 06-723536.
[13] Lebecque B, Vial JP, Pigneux A, et al. Chronic myelomonocytic leukaemia followed by blastic plasmacytoid dendritic cell neoplasm[J]. Br J Haematol, 2019, 185(3): 398. DOI: 10.1111/bjh.15794.
[14] Tsagarakis NJ, Paterakis G. Dendritic cell leukemia: a review[J]. Curr Oncol Rep, 2020, 22(6): 55. DOI: 10.1007/s11912-020-00921-y.
[15] Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm[J]. N Engl J Med, 2019, 380(17): 1628-1637. DOI: 10.1056/NEJMoa1815105.
|